Medical/Pharmaceuticals

Rhino Rescue Expands Horizons at Medica 2023, Exploring New Opportunities in the European Market

DÜSSELDORF, Germany, Nov. 28, 2023 /PRNewswire/ -- Rhino Rescue made a strong appearance at Medica inGermany, showcasing the comprehensive range of its latest technologies and products. During the event, more than 20 companies expressed their intention to partner with Rhino Rescue, thereby expand...

2023-11-28 23:00 1993

Dr. Liu Jian, President of Medicilon Drug Discovery Division, wins the Thomas Alva Edison Patent Award

BOSTON, Nov. 28, 2023 /PRNewswire/ -- Dr. Liu Jian, President of the Drug Discovery Division at Medicilon, has been awarded the Thomas Alva Edison Patent Award for 2023 from the New Jersey Research and Development Committee. This recognition stems from his innovative patent on the PCSK9 inhibitor...

2023-11-28 21:30 1957

Akeso Launches Construction of Shanghai Global R&D Center to Accelerate Its Innovation Globalization Strategy

HONG KONG, Nov. 28, 2023 /PRNewswire/ -- The groundbreaking ceremony for Akeso (9926.HK)  Shanghai Global R&D Center was successfully held at the Zhangjiang headquarters park inShanghai. The establishment of the Akeso Global R&D Center signifies a crucial step in Akeso's innovative globalization ...

2023-11-28 21:00 2773

AI-Powered TIL Analysis by Lunit Unveils Prognostic Insights for Colon Cancer - published in npj Precision Oncology

* AI-powered spatial analysis of tumor-infiltrating lymphocytes using Lunit SCOPE IO provides accurate prognosis prediction in stage II–III colon cancer SEOUL, South Korea, Nov. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and...

2023-11-27 22:05 2144

Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Met Primary Endpoint of Progression-Free Survival in Phase III Trial for First-Line Treatment of Recurrent/Metastatic Cervical Cancer in All-Comer Patients

HONG KONG, Nov. 27, 2023 /PRNewswire/ -- Akeso (9926. HK) has announced that the AK104-303 Phase III trial, which investigated cadonilimab (Akeso's PD-1/CTLA-4 bispecific antibody) combined with platinum-based chemotherapy +/- bevacizumab, has met one of its primary endpoints of progression-fre...

2023-11-27 21:30 2268

Ascentage Pharma Hosts Ceremony Marking the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication

SUZHOU, China, and ROCKVILLE, Md., Nov. 24, 2023 /PRNewswire/ -- 23 Nov, 2023, on the second anniversary of the initial approval for olverembatinib, Ascentage Pharma hosted a ceremony in Suzhou,China, marking the launch of olverembatinib in a newly approved indication and the dispatch of the firs...

2023-11-24 19:57 2720

China's First NDA for a KRAS G12C Inhibitor: NMPA Accepts New Drug Application for GFH925 and Grants GFH925 with Priority Review Designation

SHANGHAI, Nov. 24, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) ofChina has accepted the...

2023-11-24 19:00 2607

Neurophet to showcase brain image analysis technology at RSNA 2023

- Introducing Alzheimer's disease related brain image analysis technology including Neurophet AQUA and Neurophet SCALE PET - Plans to launch analysis technology for infant brain image and cerebrovascular disease SEOUL, South Korea, Nov. 23, 2023 /PRNewswire/ -- Neurophet, an artificial intellig...

2023-11-23 22:00 2553

PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak Syndrome

* Study reveals a promising avenue for addressing Idiopathic Systemic Capillary Leak Syndrome (ISCLS, a.k.a. Clarkson Disease) and vessel-related rare disease indications * Unique Tie2-activating antibody program, PMC-403, demonstrates efficacy in improving survival and reducing vascular leak...

2023-11-23 10:31 2397

Lunit's AI-Powered Mammography Analysis Solution Proves Comparable to Radiologists in Breast Cancer Detection - published in European Radiology

- A large population-based retrospective study in Denmark validates that Lunit INSIGHT MMG's accuracy is on par with that of radiologists in detecting breast cancer SEOUL, South Korea, Nov. 22, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diag...

2023-11-22 22:07 2741

United Imaging Intelligence to Unveil Cutting-edge AI Technology at RSNA

SHANGHAI, Nov. 22, 2023 /PRNewswire/ -- United Imaging Intelligence (UII), a pioneering subsidiary of United Imaging Group known for its innovative artificial intelligence (AI) applications in healthcare, is set to showcase its latest medical AI advancements at the upcoming Radiological Society o...

2023-11-22 22:00 2779

WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale

* By leveraging WuXiUPTM, WuXi Biologics has completed its first end-to-end continuous drug substance (DS) manufacturing from perfused cell culture to final UF/DF pool at pilot scale * This end-to-end continuous bioprocess, which is in place for WuXi Biologics global manufacturing network, is...

2023-11-22 13:21 4437

Baird Medical Attains FDA Clearance to Market Its Microwave Ablation System in the United States

FRISCO, Texas, Nov. 21, 2023 /PRNewswire/ -- Baird Medical Devices, Inc. ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider inChina, today announced that its subsidiary, Betters (Suzhou) Medical Co., Ltd, has received clearance from the ...

2023-11-22 06:00 1976

United Imaging Showcases Pioneering Advances and Reinforces U.S. Growth at RSNA 2023

HOUSTON, Nov. 21, 2023 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, is set to showcase its comprehensive portfolio of innovative technologies at RSNA 2023. This includes another series of global firsts and pioneering medical...

2023-11-21 14:57 1949

ST Pharm Presented '100-Day Expedite Strategy', Preparedness and Proactive Measures for Future Pandemic at Korea-CEPI R&D Workshop

SEOUL, South Korea, Nov. 20, 2023 /PRNewswire/ -- Nov. 21, 2023 local time, ST Pharm announced 'Rapid Preparedness of Pandemic Vaccine in 100 Days using ST Pharm's own mRNA Platform Technology' at the Korea-CEPI R&D Workshop in World Bio Summit 2023, organized by Korea Health Industry Development...

2023-11-21 12:00 2135

Concord Medical Schedules 2023 Annual Meeting of Shareholders

BEIJING, Nov. 20, 2023 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensi...

2023-11-21 05:00 2172

Preserving Tradition in the Digital Age: A Historic Collaboration for Digitising Bhutan's Medicinal Plants and Herbs

NEW YORK and SINGAPORE, Nov. 20, 2023 /PRNewswire/ -- In a landmark move, four eminent organisations have united under a Memorandum of Understanding (MOU) signed on17 November 2023. This alliance aims to digitise and certify Bhutan's treasured Sowa-Rigpa, the ancient Traditional Medicines know...

2023-11-20 22:00 2319

CARsgen Announces Formation of its Clinical Advisory Board

SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the formation of its Clinical Advisory Board. This highly regarded pa...

2023-11-20 21:50 3287

Porton Advanced and Ascle Therapeutics Reached a Strategic Partnership to Promote the Application of NK Cells in Cancer Prevention, Beauty, and Anti-aging

SUZHOU, China, Nov. 20, 2023 /PRNewswire/ -- On November 20, 2023, Porton Advanced announced a strategic partnership with Ascle Therapeutics to jointly develop and produce NK cells, assist in the development and innovation in gene and cell therapy, and accelerate the application of NK cells in ca...

2023-11-20 20:00 1609

First Subject Enrolled in Phase 1 Study of MRX-5

SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. (hereinafter referred to as "MicuRx") announced that its proprietary antibiotic MRX-5, has enrolled its first subject in the first Phase I clinical trial inAustralia. MRX-5 is a new type of benzodiazepine...

2023-11-20 18:34 1951
1 ... 116117118119120121122 ... 251